Browse all 651 ETFs by category, no search needed
Global 185
US market 62
Country 93
Core UCITS 15
Sector 103
Style & factor 111
Theme 45
Dividend 37
Fidelity Disruptive Medicine (FMED)Overvalued or undervalued?
Look-through valuation · Global · Expense ratio 0.50 % · ISIN US3160921470
Price history (since 2023)
Monthly close since 2023. Price shows performance, the valuation verdict is in the look-through above.
Top holdings
| Holding | Weight | vs fair value | Quality |
|---|---|---|---|
| 10X Genomics Inc TXG | 5.4 % | −71.3 % | 66 |
| Natera Inc NTRA | 4.2 % | −94.3 % | 37 |
| Thermo Fisher Scientific Inc TMO | 4.0 % | +2.6 % | 62 |
| Danaher Corporation DHR | 3.8 % | −6.2 % | 73 |
| Illumina Inc ILMN | 3.2 % | +10.0 % | 80 |
| Lifestance Health Group Inc LFST | 3.0 % | −93.3 % | 58 |
| argenx NV ADR ARGX | 2.9 % | −2.9 % | 70 |
| Revolution Medicines Inc RVMD | 2.6 % | n/a | n/a |
| Sartorius Stedim Biotech SA DIM | 2.6 % | −74.6 % | 48 |
| Alnylam Pharmaceuticals Inc ALNY | 2.4 % | −11.4 % | 66 |
| Heartflow, Inc. Common Stock HTFL | 2.4 % | n/a | n/a |
| Moderna Inc MRNA | 2.4 % | n/a | n/a |
| Intuitive Surgical Inc ISRG | 2.1 % | −11.3 % | 73 |
| Cogent Biosciences Inc UMRX | 2.1 % | n/a | n/a |
| Kymera Therapeutics Inc KYMR | 2.0 % | n/a | n/a |
| Caris Life Sciences, Inc. Common Stock CAI | 1.9 % | −81.2 % | 47 |
| West Pharmaceutical Services Inc WST | 1.8 % | −63.5 % | 71 |
| Insmed Inc INSM | 1.8 % | n/a | n/a |
| Kiniksa Pharmaceuticals Ltd KNSA | 1.8 % | −82.2 % | 56 |
| Repligen Corporation RGEN | 1.8 % | −56.4 % | 67 |
| Vaxcyte Inc PCVX | 1.8 % | n/a | n/a |
| Ascendis Pharma AS ASND | 1.8 % | −82.0 % | 60 |
| Edwards Lifesciences Corp EW | 1.7 % | −5.5 % | 67 |
| Guardant Health Inc GH | 1.7 % | n/a | n/a |
| BrightSpring Health Services, Inc. Common Stock BTSG | 1.6 % | −60.3 % | 42 |
Fair value and quality per position come from the same valuation as our stock pages. Showing the 25 largest of 48 disclosed positions. "n/a" means the position is not (yet) in our stock universe and does not enter the average.
The 10 most cheaply valued ETFs
Measured against the look-through fair value of the holdings (sufficiently covered funds only). Green means below fair value, red above. Not financial advice.
- 1 CHIU Global X MSCI China Utilities ETF +87.2 % below FV
- 2 FXI iShares China Large-Cap ETF +57.2 % below FV
- 3 FCFY First Trust S&P 500 Diversified Free Cash Flow ETF +43.7 % below FV
- 4 MCHI iShares MSCI China ETF +41.9 % below FV
- 5 ITB iShares U.S. Home Construction ETF +31.4 % below FV
- 6 TAN Invesco Solar ETF +26.0 % below FV
- 7 C003 Amundi Index Solutions - Amundi DivDAX I UCITS ETF EUR Distributing +19.4 % below FV
- 8 FDNI First Trust Dow Jones International Internet ETF +19.3 % below FV
- 9 ESPO VanEck Video Gaming and eSports ETF +18.3 % below FV
- 10 XIDV Franklin International Dividend Booster Index ETF +17.9 % below FV
Frequently asked about FMED
Is FMED overvalued?
What is the fair value of FMED?
How do you calculate the fair value of an ETF?
Which stocks drive the valuation of FMED?
What is the expense ratio of FMED?
How we value this ETF
An ETF has no fair value of its own like a single stock. We build it bottom up: every holding has a fair value and a quality score on our pages. Weighted by portfolio share, that gives Fidelity Disruptive Medicine ETF an average of how cheap or expensive its companies currently sit versus fair value, and how high their average quality is.
As of: Sep 25, 2026
The look-through is a computed summary of public fundamentals and is no substitute for your own research.